Roundup Lawsuit Cancers: Full Eligibility Guide 2026

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

Non-Hodgkin lymphoma is the cancer most closely tied to the Roundup lawsuit, but it’s not the only one. Several blood cancers and lymphatic system cancers are included in claims against Bayer and its former subsidiary Monsanto.

Understanding what cancers are included in the Roundup lawsuit matters right now. Thousands of claims are still active in 2026, and new claimants continue to come forward with diagnoses linked to glyphosate, the active chemical in Roundup weed killer.

This guide covers every eligible cancer type, the science behind the claims, who qualifies, what settlements look like, and how to file before time runs out.

Also worth exploring: Education Lawsuit Last Week: 2026 Payout and Filing Guide

One fact that might surprise you: over 160,000 Roundup lawsuits have been filed since litigation began, making this one of the largest mass tort cases in U.S. history.

What Cancers Are Included in the Roundup Lawsuit?

The Roundup lawsuit primarily covers non-Hodgkin lymphoma and its subtypes, along with certain leukemia diagnoses and other blood-related cancers.

These are the main cancer categories included in active Roundup litigation as of 2026:

• Non-Hodgkin lymphoma (NHL) and all major subtypes
• B-cell lymphoma (multiple forms)
• T-cell lymphoma
• Chronic lymphocytic leukemia (CLL)
• Hairy cell leukemia
• Mantle cell lymphoma
• Follicular lymphoma
• Diffuse large B-cell lymphoma (DLBCL)
• Marginal zone lymphoma

The connecting thread across all of these is the lymphatic and blood systems. Glyphosate has been studied for its potential to damage DNA in white blood cells, which is where these cancers originate.

If your diagnosis falls outside of these categories, you may still want to speak with an attorney. The science is evolving, and some claims involving other blood cancers are being evaluated on a case-by-case basis.

Roundup Cancer Lawsuit 2026: Where Things Stand Now

As of 2026, the Roundup cancer lawsuit is still very much active, with tens of thousands of unresolved claims still working through the courts.

Bayer agreed to a landmark $10.9 billion settlement in 2020 to resolve a large portion of existing claims. But that settlement did not end all litigation. Bayer has continued to fight new cases in state and federal courts, and appeals are ongoing at multiple levels.

In 2023, the U.S. Supreme Court declined to shield Bayer from future state-court lawsuits. That decision opened the door for a fresh wave of claims and gave existing claimants stronger footing.

Bayer has set aside additional reserves to handle ongoing and future claims. If you haven’t filed yet and have a qualifying diagnosis, 2026 may be your final window.

Full List of Roundup Lawsuit Eligible Cancers

The complete list of cancers eligible for the Roundup lawsuit centers on hematologic cancers, meaning cancers of the blood and lymphatic system.

Here is the full breakdown attorneys and courts have recognized as eligible in Roundup mass tort claims:

Lymphomas:

• Diffuse large B-cell lymphoma (DLBCL)
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Burkitt lymphoma
• Peripheral T-cell lymphoma
• Cutaneous T-cell lymphoma
• Anaplastic large cell lymphoma
• Primary mediastinal B-cell lymphoma

Leukemias:

• Chronic lymphocytic leukemia (CLL)
• Hairy cell leukemia
• Small lymphocytic lymphoma (SLL)

Other blood-related cancers may qualify depending on evidence and diagnosis specifics.

The key distinction here: Hodgkin lymphoma is typically not included, because its biological profile differs enough from the glyphosate-cancer link that courts have generally not supported those claims.

Bold stat: Diffuse large B-cell lymphoma accounts for roughly 30 to 35 percent of all NHL diagnoses in the U.S., making it the most commonly claimed cancer type in Roundup lawsuits.

Key Takeaway: The Roundup lawsuit covers a broad range of blood and lymphatic cancers, with non-Hodgkin lymphoma and its subtypes being the most clearly established and most commonly litigated diagnoses.

Non-Hodgkin Lymphoma and the Roundup Lawsuit

Non-Hodgkin lymphoma is the anchor cancer in the Roundup lawsuit. It’s the diagnosis that first put Monsanto in court and the one with the strongest scientific support.

NHL is a group of blood cancers that affect the lymphatic system. The lymphatic system is your body’s immune network, a series of nodes and vessels that help fight infection. When glyphosate disrupts normal cell function in lymph tissue, the result can be uncontrolled cell growth, which is the definition of lymphoma.

The scientific foundation for NHL claims comes from the International Agency for Research on Cancer (IARC), which classified glyphosate as a “probable human carcinogen” (Group 2A) in 2015. That classification specifically cited epidemiological evidence linking glyphosate to NHL.

Three landmark jury trials involving NHL diagnoses resulted in verdicts against Monsanto, with combined damages exceeding $2 billion before reductions on appeal. These verdicts set the tone for the broader settlement.

Roundup Lawsuit NHL Subtypes: Which Ones Qualify?

Not all NHL diagnoses are identical, and courts have recognized specific subtypes based on their biological connection to glyphosate exposure.

NHL is actually an umbrella term covering more than 60 distinct cancer types. In the Roundup litigation, the subtypes with the strongest claim history include:

• Diffuse large B-cell lymphoma (DLBCL): The most common and most litigated subtype.
• Follicular lymphoma: A slow-growing form with strong epidemiological links.
• Marginal zone lymphoma: Recognized in multiple settled claims.
• Small lymphocytic lymphoma (SLL): Closely related to CLL; frequently included.
• Burkitt lymphoma: Less common but has appeared in filed claims.
• T-cell lymphomas: Peripheral and cutaneous subtypes have been included.

The subtype matters for your claim because it affects how attorneys build your case and how claim administrators assign payout tiers.

Your pathology report from diagnosis will identify your specific subtype. That document is one of the most important pieces of evidence you’ll need when filing.

Does B-Cell Lymphoma Qualify for the Roundup Lawsuit?

B-cell lymphoma qualifies for the Roundup lawsuit, and it’s actually the most common type of lymphoma seen in Roundup claims.

B-cells are white blood cells that produce antibodies. They’re part of the immune system, and they’re the cell type most associated with glyphosate-related cancer in the research literature. When these cells mutate due to toxic exposure, the result is a B-cell lymphoma.

The most common B-cell lymphomas in Roundup litigation:

• Diffuse large B-cell lymphoma (DLBCL)
• Follicular lymphoma (also B-cell origin)
• Mantle cell lymphoma (B-cell origin)
• Marginal zone lymphoma (B-cell origin)
• Small lymphocytic lymphoma (B-cell origin)
• Primary mediastinal B-cell lymphoma

Essentially, the majority of cancers included in the Roundup lawsuit are B-cell cancers. If your diagnosis mentions “B-cell” anywhere in the pathology report, you almost certainly have a qualifying cancer type.

Bold callout: B-cell lymphomas make up approximately 85 percent of all NHL diagnoses, which explains why so many Roundup claimants have NHL as their primary diagnosis.

Key Takeaway: B-cell lymphomas are the most common cancers in Roundup claims because glyphosate research most directly implicates B-cell mutations, and these subtypes dominate the active litigation landscape in 2026.

Roundup Lawsuit and Leukemia: What You Need to Know

Certain leukemia types are included in the Roundup lawsuit, though they represent a smaller share of total claims compared to NHL.

Leukemia is a cancer of the blood-forming tissues, including the bone marrow. Some leukemias share biological features with the lymphomas at the center of this litigation, which is why they’ve been incorporated into the same mass tort claims.

The leukemia types recognized in Roundup litigation include:

• Chronic lymphocytic leukemia (CLL): This is the most common leukemia in adults and the one most frequently cited in Roundup claims. CLL and small lymphocytic lymphoma (SLL) are considered different stages of the same disease.
• Hairy cell leukemia: A rare but recognized leukemia type in active Roundup claims. Its name comes from the appearance of abnormal B-cells under a microscope.

Acute leukemias (like AML or ALL) are generally not included in standard Roundup claims. The litigation has focused on chronic and lymphocytic forms because of their closer biological ties to lymphoma.

If you have CLL or hairy cell leukemia and used Roundup, your diagnosis falls within the recognized category of covered conditions.

Mantle Cell Lymphoma and the Roundup Lawsuit

Mantle cell lymphoma qualifies for the Roundup lawsuit and has appeared in numerous settled and active claims.

Mantle cell lymphoma (MCL) is a B-cell NHL that originates in the “mantle zone” of the lymph node. It’s considered an aggressive form of lymphoma and typically affects older adults. Because it’s a B-cell NHL, it falls squarely within the category of cancers covered in Roundup litigation.

MCL accounts for roughly 5 to 7 percent of all NHL diagnoses in the U.S. It’s less common than DLBCL or follicular lymphoma, but courts and claims administrators have recognized it as a qualifying diagnosis.

A few key points about MCL claims:

• Your diagnosis must be confirmed by pathology, not just clinical assessment.
• Treatment records and staging documents strengthen your claim significantly.
• MCL claims have appeared in both the federal MDL proceedings and individual state court actions.

Quick Facts: Mantle Cell Lymphoma in Roundup Claims

If you were diagnosed with MCL and have a history of Roundup exposure, this is one of the cleaner claim types because the diagnosis is specific and the scientific connection to B-cell NHL is well-documented.

Key Takeaway: Mantle cell lymphoma, chronic lymphocytic leukemia, and hairy cell leukemia are all recognized qualifying diagnoses in Roundup litigation, expanding the lawsuit’s reach beyond the more well-known non-Hodgkin lymphoma cases.

The Glyphosate Cancer Lawsuit: Science Behind the Claims

The entire Roundup lawsuit rests on one core scientific argument: glyphosate, the active ingredient in Roundup, causes cancer in humans.

Glyphosate is a broad-spectrum herbicide that kills plants by blocking a specific enzyme pathway. Monsanto, now owned by Bayer, introduced it in the 1970s, and Roundup became the best-selling weed killer in the world. For decades, Monsanto maintained it was safe for humans.

That changed in 2015 when the IARC, the cancer research arm of the World Health Organization, reviewed existing studies and classified glyphosate as a Group 2A probable human carcinogen. The classification was based on:

• Studies showing increased NHL risk in agricultural workers
• Animal studies showing cancer development after glyphosate exposure
• Mechanistic evidence that glyphosate can damage DNA

The EPA has taken a different position, maintaining that glyphosate is unlikely to cause cancer at typical exposure levels. This disagreement between agencies has been central to courtroom battles.

Importantly, juries have sided with plaintiffs in multiple high-profile trials. Jurors found that Monsanto knew about cancer risks and failed to warn users, which is the basis for punitive damages awarded in early cases.

Don't miss this — Shocking Entertainment Lawsuit 2026: Claims and Payouts

Roundup Exposure and Cancer Link: What the Research Shows

The scientific connection between Roundup exposure and cancer has been debated for years, but the research supporting the plaintiffs’ position is substantial.

A major review published in the journal Mutation Research analyzed agricultural health studies and found that high exposure to glyphosate was associated with a 41 percent increased risk of developing NHL. This figure became one of the most cited statistics in Roundup trial proceedings.

Think of it like secondhand smoke. For years, tobacco companies argued the evidence wasn’t conclusive. But enough studies stacked up that courts, juries, and eventually public opinion shifted. The Roundup litigation follows a similar pattern.

Research highlights relevant to active 2026 claims:

• Agricultural workers and landscapers show the highest exposure levels and the strongest cancer associations in epidemiological studies.
• Long-term exposure (defined as more than 10 days per year for multiple years) is consistently cited as a key risk factor.
• Internal Monsanto documents revealed during discovery suggested company scientists were aware of potential cancer links earlier than public statements acknowledged.

Bold stat: The 2019 meta-analysis cited in Hardeman v. Monsanto found a statistically significant association between glyphosate-based herbicide use and NHL, specifically in the highest exposure categories.

Who Qualifies for the Roundup Lawsuit?

You may qualify for the Roundup lawsuit if you used Roundup or another glyphosate-based herbicide and were later diagnosed with a qualifying cancer.

The basic eligibility framework attorneys use looks like this:

1. Exposure: You used Roundup, another Monsanto glyphosate product, or a glyphosate-based herbicide.
2. Diagnosis: You were diagnosed with a qualifying cancer (NHL, B-cell lymphoma, CLL, hairy cell leukemia, or related blood cancers).
3. Causation: Your exposure preceded your diagnosis by at least one to two years, allowing a reasonable “latency period” for cancer development.

People with the strongest claims tend to include:

• Farmers and agricultural workers with years of regular exposure
• Landscapers, groundskeepers, and golf course workers
• Homeowners who used Roundup regularly in yards or gardens
• Municipal workers who applied herbicides to roadsides or public spaces

Family members of someone who died from a qualifying cancer may also be eligible to file a wrongful death claim on behalf of the estate.

Roundup Lawsuit Eligibility Requirements Explained

Beyond the basic “exposure plus diagnosis” formula, specific eligibility requirements can affect whether your claim moves forward and how much it’s worth.

Here is what claim administrators and attorneys typically evaluate:

Exposure Documentation:

• Can you show when and how often you used Roundup?
• Do you have purchase receipts, employment records, or witness statements confirming your use?
• Was your exposure occupational (stronger claims) or residential (still eligible but typically harder to document)?

Medical Records:

• A confirmed pathology diagnosis is non-negotiable. Clinical notes alone are not enough.
• Staging records, treatment history, and oncologist reports all strengthen the claim.
• A diagnosis date that post-dates your exposure by at least one year is standard.

Statute of Limitations:

• Each state has its own deadline for filing personal injury or product liability claims.
• Most states allow two to three years from the date of diagnosis or discovery of the cancer link.
• Missing this deadline generally bars you from filing entirely.

Claim Strength Factors:

Key Takeaway: Strong Roundup claims combine documented, long-term exposure with a confirmed pathology diagnosis of an eligible cancer, and the most valuable claims come from occupational users who can prove years of regular direct contact with glyphosate products.

Roundup Settlement Amounts in 2026: What to Expect

Settlement amounts in the Roundup lawsuit vary significantly based on cancer severity, exposure history, and where in the litigation process your claim sits.

Bayer’s 2020 settlement of approximately $10.9 billion was designed to cover existing and future claims. But individual payouts within that framework range widely.

General settlement ranges that have been reported across the litigation:

• Lower tier claims: $5,000 to $40,000 (typically weaker exposure documentation or less severe cancer)
• Mid-tier claims: $40,000 to $150,000 (clear exposure history, significant cancer impact)
• High-value claims: $150,000 to $500,000 or more (strong exposure proof, aggressive cancer, significant medical treatment)
• Trial verdicts (if litigated): Several individual verdicts have exceeded $1 million before appeals and reductions

It’s worth noting that punitive damages awarded in early jury trials were reduced significantly on appeal. The Johnson verdict, originally $289 million, was reduced to approximately $20 million. The Pilliod verdict, originally $2 billion, was reduced to approximately $87 million.

These figures are based on reported settlements and public court records, not guarantees.

Roundup Lawsuit Payout Per Person: Tiers and Factors

The payout per person in the Roundup lawsuit is not a flat amount. It’s calculated based on a tiered system that weighs multiple factors.

Claims administrators evaluate each case individually. The factors that push a claim into a higher payout tier include:

Cancer Severity:

• Stage at diagnosis (Stage III or IV typically leads to higher awards)
• Whether the cancer was aggressive or slow-growing
• Treatment required (chemotherapy, stem cell transplant, radiation, etc.)
• Whether the cancer recurred or became terminal

Exposure Level:

• Number of years using Roundup
• Frequency of application per year
• Whether exposure was occupational or residential
• Whether protective equipment was used (less protection often equals stronger claim)

Age and Life Impact:

• Younger claimants with longer expected lifespan affected by cancer typically receive higher awards
• Lost income, disability, and reduced quality of life are factored in

Documentation Quality:

• Medical records going back to diagnosis
• Employment records or purchasing records showing Roundup use
• Expert testimony linking your specific cancer to glyphosate exposure

Think of this like an insurance claim. The more evidence you can stack up showing the damage and its cause, the stronger your payout position becomes.

Bayer Roundup Settlement Update 2026

Bayer’s legal position on Roundup in 2026 is still evolving, and the company faces ongoing financial pressure from remaining claims.

After the 2020 settlement, Bayer initially set aside approximately $10.9 billion to cover claims. The company later increased its litigation reserves as new claims continued to mount. By 2025, Bayer had spent billions on settlements and continued to face appellate rulings that kept state-court claims alive.

Key 2026 updates:

• Bayer has not reached a global resolution for all pending claims. Individual claims and small group settlements continue.
• The company has explored legislative solutions at the federal level to limit future liability, but no federal preemption bill has passed as of 2026.
• Several state appellate courts have upheld jury verdicts against Bayer, reinforcing plaintiffs’ ability to argue failure-to-warn claims.
• New scientific studies published in 2024 and 2025 have continued to add to the body of evidence linking glyphosate to NHL.

Bayer has stated it believes Roundup is safe when used as directed, a position it has maintained throughout the litigation. But courts have repeatedly found otherwise.

Key Takeaway: Bayer’s 2020 settlement did not end the Roundup litigation. Thousands of claims remain active in 2026, and new scientific and legal developments continue to favor claimants with qualifying diagnoses.

Along the same lines: McDonald’s McRib Lawsuit 2026: Claims, Who Qualifies

How to File a Roundup Cancer Claim

Filing a Roundup cancer claim starts with connecting your diagnosis to your glyphosate exposure and then working with a mass tort attorney to submit your case.

Here is the general process:

Something similar worth reading: Reed-Nelson Lawsuit 2026: Settlement and Payout Guide

Step 1: Confirm Your Diagnosis
Get your full pathology report. You need a documented, confirmed diagnosis of a qualifying cancer. This is non-negotiable.

Step 2: Document Your Exposure
Gather everything that shows you used Roundup. This includes:

• Purchase receipts from hardware or garden stores
• Employment records if you were a professional applicator
• Witness statements from neighbors, coworkers, or family
• Photos of Roundup products you used

Step 3: Consult a Mass Tort Attorney
Most Roundup attorneys work on contingency, meaning they only get paid if you win or settle. You pay nothing upfront. Attorneys will evaluate your case, pull your medical records, and determine the claim tier.

Step 4: File Your Claim
Your attorney will either file in federal court under the MDL, in state court, or submit directly to a claims administrator depending on where things stand in 2026.

Step 5: Wait for Settlement or Trial
Most claims settle before trial. Your attorney will negotiate on your behalf. If settlement offers are too low, the case can proceed to trial.

Most people are surprised by how simple the intake process is. The attorney does the heavy lifting once you have the basic documentation together.

Roundup Lawsuit Filing Deadline 2026: Don’t Miss It

The filing deadline for the Roundup lawsuit depends on your state’s statute of limitations and your diagnosis date, and missing it can permanently disqualify your claim.

Every state sets its own statute of limitations for personal injury and product liability cases. For Roundup claims, the clock typically starts either:

• On the date of your cancer diagnosis, or
• On the date you “discovered” or should have discovered that Roundup may have caused your cancer

Most states allow two to three years from one of those trigger dates to file. Some states have shorter windows.

States with specific considerations:

• California: Two years from discovery
• Texas: Two years from diagnosis
• New York: Three years from diagnosis
• Florida: Two years (reduced from four years in recent legislative changes)

If you were diagnosed years ago, the discovery rule may still protect you. If you didn’t know Roundup could be the cause until recently, your clock may not have started yet.

Do not assume you’ve missed the deadline without checking. Many people diagnosed five or more years ago are still filing valid claims in 2026 based on the discovery rule.

Frequently Asked Questions

What types of cancer qualify for the Roundup lawsuit?

Non-Hodgkin lymphoma and its subtypes are the primary qualifying cancers for the Roundup lawsuit.

Chronic lymphocytic leukemia, hairy cell leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma are all recognized in active claims.

Hodgkin lymphoma and solid tumors are generally not included.

How much money can you get from a Roundup lawsuit settlement?

Settlement amounts range from a few thousand dollars to several hundred thousand dollars depending on your case.

Factors like cancer severity, exposure duration, documentation quality, and cancer type all affect the final amount.

High-value cases with strong occupational exposure records and aggressive cancer diagnoses have settled in the $150,000 to $500,000-plus range.

How long does a Roundup cancer lawsuit take to settle?

Most Roundup claims take one to three years from filing to resolution.

Cases that are part of existing settlement programs can move faster, sometimes within six to twelve months.

Claims that go to trial take significantly longer, sometimes three to five years or more.

Can family members of someone who died from cancer file a Roundup lawsuit?

Yes, family members can file a wrongful death claim on behalf of someone who died from a qualifying cancer linked to Roundup exposure.

The estate or surviving spouse typically has standing to file, and the same eligibility requirements apply regarding exposure history and diagnosis.

Deadlines for wrongful death claims are similar to personal injury deadlines and vary by state.

Does the Roundup lawsuit cover people who only used it a few times?

People who used Roundup only a small number of times may still have a viable claim, but these cases are harder to win.

The strongest claims involve regular, long-term use, particularly in occupational settings like farming or landscaping.

Attorneys will evaluate your specific situation to determine whether the exposure level is sufficient to support a claim.

Where Things Go From Here

The Roundup lawsuit is still one of the most significant mass torts in American legal history, and it’s still open. If you or someone you love was diagnosed with non-Hodgkin lymphoma, B-cell lymphoma, CLL, or another qualifying blood cancer after using Roundup, a potential claim deserves serious attention in 2026.

Gather your diagnosis records and document your exposure history. Time limits are real, and every state has a deadline that can cut off your right to file.

The process starts with a free consultation with a mass tort attorney. That’s the single best next step you can take today.

the Roundup Lawsuit” appears in large white and gold typography centered in the upper two thirds of the composition. Below the headline, a stylized silhouette of a person standing in an agricultural field is visible in dark tones against a subtly illuminated horizon. Legal scales icon and a medical cross symbol appear as gold graphic accents flanking the figure. The left third of the image has open breathing room for optional text overlay. Lighting is dramatic and low contrast with soft gold lens flare near the horizon. Clean, modern editorial design aesthetic similar to Bloomberg Law or Reuters legal reporting. No real faces. No watermarks. No logos. No stock photo feel.

Don't miss this — Aptive Environmental Lawsuit 2026: Claims, Payouts & Filing

On a related note, check out AFFF Lawsuit Tiers 2026: Payouts, Eligibility and How It Works

For a deeper understanding, check Finance Lawsuit April 2026: Settlement and Payout Updates

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.